Published
## Filings that contain financial statements The following Form 8-Ks furnish Abbott's quarterly earnings press release as Exhibit 99.1, and each one contains a full condensed consolidated statement of earnings (with a GAAP-to-adjusted reconciliation) for the period named: - Accession 0001628280-26-048377 (filed July 16, 2026) — second-quarter and first-half 2026 results (period ended June 30, 2026), with GAAP and non-GAAP income statements and segment sales tables. - Accession 0001628280-26-025365 (filed April 16, 2026) — first-quarter 2026 results (period ended March 31, 2026), with GAAP and non-GAAP income statements and segment sales tables. - Accession 0001628280-26-002982 (filed January 22, 2026) — fourth-quarter and full-year 2025 results (period ended December 31, 2025), with GAAP and non-GAAP income statements, segment sales tables, and 2026 financial guidance. - Accession 0001628280-25-045049 (filed October 15, 2025) — third-quarter 2025 results (period ended September 30, 2025), furnished in the same recurring earnings-release format. - Accession 0001628280-25-035135 (filed July 17, 2025) — second-quarter 2025 results (period ended June 30, 2025), furnished in the same recurring earnings-release format. ## Second-quarter 2026 earnings and guidance On July 16, 2026, Abbott reported second-quarter 2026 net sales of $12.593 billion, up 13.0 percent on a reported basis and 4.8 percent on a comparable basis, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31. Abbott reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5% and raised its full-year 2026 adjusted diluted EPS guidance to $5.45–$5.60, up from a prior range of $5.38–$5.58. The company also said it returned $2.1 billion to shareholders in the quarter through dividends and share repurchases. (Accession 0001628280-26-048377.) ## First-quarter 2026 earnings and updated guidance for the Exact Sciences acquisition On April 16, 2026, Abbott reported first-quarter 2026 net sales of $11.164 billion, up 7.8 percent on a reported basis and 3.7 percent on a comparable basis, with GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15. Abbott updated its full-year 2026 adjusted diluted EPS guidance to $5.38–$5.58, which it said includes $0.20 of dilution related to the newly closed Exact Sciences acquisition, while reaffirming full-year comparable sales growth guidance of 6.5% to 7.5%. (Accession 0001628280-26-025365.) ## Fourth-quarter and full-year 2025 earnings; initial 2026 guidance On January 22, 2026, Abbott reported fourth-quarter 2025 sales of $11.459 billion, up 4.4 percent on a reported basis, with GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.50. Full-year 2025 sales were $44.328 billion, up 5.7 percent, with GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15. Abbott issued initial full-year 2026 guidance of 6.5%–7.5% organic sales growth and adjusted diluted EPS of $5.55–$5.80. The release also reconfirmed that the pending Exact Sciences acquisition was expected to close in the second quarter of 2026. (Accession 0001628280-26-002982.) ## Acquisition of Exact Sciences: signing, financing, and closing - **November 19–20, 2025 — Merger agreement signed.** Abbott entered into an Agreement and Plan of Merger with Exact Sciences Corporation and its merger subsidiary, Badger Merger Sub I, Inc., under which each Exact Sciences share would convert into the right to receive $105.00 in cash. Abbott also entered into a $20 billion senior unsecured bridge loan commitment letter with Morgan Stanley Senior Funding to help finance the deal. (Accession 0001104659-25-114422; Exhibit 2.1 is the merger agreement.) - **February 23, 2026 — Notes pricing agreement.** Abbott priced $20 billion of senior notes across eight tranches (floating-rate and fixed-rate notes maturing 2029–2066), intended to help fund the Exact Sciences acquisition consideration and repay Exact Sciences debt. (Accession 0001104659-26-020509.) - **March 9, 2026 — Notes offering completed.** Abbott completed the $20 billion notes offering. The notes carry a special mandatory redemption at 101% of principal plus accrued interest if the Exact Sciences acquisition is not completed by the applicable outside date or if Abbott abandons the deal. (Accession 0001104659-26-025240.) - **March 23, 2026 — Acquisition completed.** Abbott completed the acquisition of Exact Sciences; Merger Sub merged into Exact Sciences, which became a direct, wholly owned Abbott subsidiary, with each Exact Sciences share converted into $105.00 in cash. The closing established Abbott's Cancer Diagnostics business and made Exact Sciences' historical results part of Abbott's comparable-sales base going forward. (Accession 0001104659-26-033079.) ## Litigation: preterm infant formula (NEC) claims - **April 10, 2026 — Derivative litigation settlement approved.** In the consolidated shareholder derivative proceeding *In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation*, the U.S. District Court for the Northern District of Illinois preliminarily approved a proposed settlement and scheduled a final settlement hearing. (Accession 0001104659-26-044892.) - **August 20, 2026 — Settlement of Gill verdict and related claims.** After the Missouri Court of Appeals affirmed a $495 million jury verdict against Abbott in the *Gill* case (originally awarded July 2024), Abbott chose to settle rather than continue appealing or pay the roughly $600 million judgment plus interest. Abbott entered agreements resolving the Gill case and necrotizing enterocolitis (NEC) claims on behalf of approximately 2,000 additional infants, for an aggregate of approximately $670 million. Abbott said the settlement follows a string of favorable rulings for preterm-formula manufacturers, including a Seventh Circuit affirmance of a pretrial judgment for Abbott in a federal MDL bellwether case. After the settlement, Abbott said roughly 1,700 lawsuits covering about 12,700 individual infants remained pending; Abbott stated the settlement is a compromise of disputed claims and not an admission of liability, and that it continues to stand by the safety of its preterm infant formula products. (Accession 0001104659-26-099247.) ## Capital return Abbott has continued its long-running dividend program throughout the period: a $0.63 per share quarterly dividend was declared in December 2025 (408th consecutive quarterly dividend, payable February 2026), February 2026 (409th, payable May 2026), and June 2026 (410th, payable August 2026). Abbott says it has raised its dividend for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index. (Accessions 0001628280-26-002982, 0001628280-26-025365, 0001628280-26-048377.) ## Governance and administrative matters - **December 12, 2025** — Nita Ahuja, M.D. was named to Abbott's board of directors; the board expanded to thirteen members effective that date. (Accession 0001104659-25-120657.) - **February 20, 2026** — The board amended Abbott's by-laws to reduce the board to twelve members, effective April 24, 2026. (Accession 0001104659-26-018167.) - **April 24, 2026 — Annual meeting.** Shareholders elected Abbott's full slate of twelve director nominees, ratified Ernst & Young LLP as auditor, approved (on an advisory basis) named-executive-officer compensation, and approved the new 2026 Incentive Stock Program and the 2026 Employee Stock Purchase Plan for Non-U.S. Employees. The same day, the board named Kevin Conroy to the board and amended the by-laws to expand the board from twelve to thirteen members. (Accession 0001104659-26-049434.) - **November 18–21, 2025** — Abbott disclosed a blackout period under its U.S. and Puerto Rico employee stock retirement plans (recordkeeper, trustee, and custodian changes), running from approximately December 24, 2025 through the week of January 11, 2026, during which plan participants could not trade in their plan accounts. (Accession 0001104659-25-114995.) Abbott's other 8-K filings in this period (routine debt-indenture officers' certificates, legal opinions, and cover-page-only filings) did not disclose additional information beyond what is summarized above.